Skip to main content
Premium Trial:

Request an Annual Quote

VC Investor Launches $125M Life Sciences Fund

NEW YORK (GenomeWeb News) – Excel Venture Management, a venture capital firm based in Boston, announced today that it has launched the Excel Medical Fund with $125 million to be invested in early- to late-stage life science platform companies.

Excel said that the new fund will focus its investments on healthcare information technology, services, diagnostics, medical devices, and life sciences platforms with applicability to adjacent industries such as energy, chemicals, defense, and agriculture.

The new fund also has already established investments in two genomics industry players: BioTrove and Synthetic Genomics.

The investment team for the fund includes Managing Directors Rick Blume, Steven Gullans, Juan Enriquez, and Enrico Petrillo; Venture Partner Donald Crothers; and Vice Presidents Caleb Winder and Tricia Moriarty.

"Excel's portfolio will be balanced across the many interrelated sectors that are impacted by life science technologies," Enriquez said in a statement. "The rapid adoption and expansion of these technologies into major industries such as energy, chemicals, defense, and agriculture represents an enormous investment opportunity. We believe that we are just seeing the tip of the iceberg."

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.